Clinical trial
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity…
NCT00116168 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00116168 |
|---|---|
| Title | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528 |
| Official title | A Phase I, Open Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528, a Humanized Monoclonal Anti-Interleukin-9 Antibody, in Healthy Adult Volunteers |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Biological |
| Interventions | MEDI-528 0.3 mg/kg, MEDI-528 1 mg/kg, MEDI-528 3 mg/kg, MEDI-528 9 mg/kg |
| Enrollment | 29 |
| Start date | Jun 1, 2005 |
| Primary completion | Apr 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Jun 28, 2005 |
| Last update posted | Dec 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: